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Recent studies have shown that in addition to Langer-
hans cells, keratinocytes can play an active role in im-
munologic events. As detected by the thymocyte ~o­
stimulator assay keratinocytes produce a factor with 
interleukin-1 (IL,-1)/leukocytic pyrogen (LP)-like activ-
ity termed epidermal cell-derived thymocyte-activating 
factor (ETAF). ETAF like IL-1/LP can mediate fev~r. 
By gel filtration and isoelectric focusing the fever-m-
ducing activ ity and the ETAF activity in the thymocyte 
assay co-purify. ETAF activity could be eliminated us-
ing a heterologous antibody against IL-1/LP. This anti-
body couid also be used to immunoprecipitate -~TAF. 
ET AF and IL-1/LP induce a peripheral neutrophilia and 
in vitro are chemotactic for neutrophils. Recently, 
ETAF has been shown to be a potent T-cell chemoat-
tractant. ET AF -containing preparations have also been 
shown to stimulate hepatocytes in vitro to synthesize 
acute phase plasma proteins. In the case of rat hepato-
cytes, this can be explained by elevated levels of mRN ~' 
although recent purifications have suggested that this 
hepatocyte-stimulating factor may be separable from 
the co-stimulator activity. ET AF has also been shown to 
induce muscle proteolysis in vitro. In addition to its 
effect on inflammatory and immune events, ETAF has 
growth promoting effects on keratinocytes and fibro-
blasts. Thus, ET AF has a multiplicity of divergent bio-
logic effects. It remains to be determined whether the 
multiplicity of these effects are subserv~d by a s~ngle 
cytokine or by a family of related cytokmes. In either 
case ET AF may play an important role in both local cuta~eous and systemic inflammatory and immune 
events. 
Until rel at ively recently, the skin was considered solely a 
target for immune- mediated damage rather than a P?Ss!ble site 
for the initiation of immunologic events. The mam mterest 
immunologists had in skin was based on elic itation and meas-
urement of delayed-type hypersensitivity reactions. Over the 
past decade, it has also become clear that the skin can be a 
target for immunologically induced injury mediated by antibod-
ies or by circulating immune complexes. These types of mJury 
may be manifested as vesiculobullous disease or as immune 
complex vasculitis. It now appears that in addition to being a 
target for immunologic injury, the skin and particularly the 
epidermis, actively participate in various immunologic ~roc­
esses and thus may serve as the peripheral-most limb of the 
immune system. 
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EPIDERMAL CELL-DERIVED THYMOCYTE-
ACTIVATING FACTOR 
The concept of the skin's passive role in immune-mediated 
reactions has been changing. In 1971, Si lberberg suggested that 
epidermal Langerhans cells play a role in contact hypersensi-
tivity [1], although proof of the involvement of Langerhans 
cell s in immune function did not come until 1978 with the 
studies of Sting! et al [2] who demonstrated that Langerhans 
cells cou ld stimulate allogeneic T cells . Since that time, the 
function of Langer hans cells, in particular t heir role in T -cell 
activation, has been the subject of intensive investigation. Since 
Langerhans cells play an obligate role in ep idermal cell-driven 
antigen-specific and allogeneic T -cell activation, studies were 
undertaken to investigate whether Langerhans cells, like mac-
rophages, produce interleukin-1 (IL-l) . Using heterogeneous 
populations of normal murine and human epidermal cells con· 
taining Langerhans cells, keratinocytes, and melanocytes we 
found that culture supernatant from these cells contained IL-
l-like activity. At that time, methods were not available to 
significantly enrich for Langer hans cells, so we used a depletion 
method to determine whether Langerhans cells were necessary 
for factor production. Under nonpathologic states, Langerhans 
cells are the on ly !a-bearing cells in the epidermis. Thus, if 
epidermal cells are treated with anti-Ia antiserum plus comple-
ment, one can eliminate the Langerhans cells from the remain-
ing epidermal cells. Using this Langerhans cell depleted popu-
lation, we found, somewhat unexpectedly that epidermal cells 
devoid of Langerhans cells produced a factor similar to IL-l. 
Since the term IL-l was restricted to a factor produced by cells 
of monocyte/ macrophage lineage, we termed this epidermal 
factor epidermal cell thymocyte-activating factor (ETAF) [3]. 
In paralle l studies, it was found that ETAF was produced by 
the spontaneously transformed keratinocyte cell line PAM 212 
[4]. 
While these initial studies revealed that Langerhans cells 
were not needed for ETAF/IL-1 production, they did not di-
rectly address the issue of whether Langerhans cells could 
produce ETAF/IL-1. Using a panning technique based on the 
method of Wysocki and Sato [5] we were able to obtain a highly 
enriched population of human Langerhans cells (up to 97%). 
Then , using this enriched population, we were able to show 
that Langerhans cells constitutively produced a factor with 
ETAF/ IL-1 activity. These studies were performed using 1 X 
106 cells/ml, so that the contaminating keratinocytes would be 
insufficient in number to yield activity in the standard ETAF/ 
IL-l assay [6]. The Langerhans cell-derived factor had the 
same molecular weight as IL-l and activity of t his Langerhans 
ce ll -derived factor could be inhibited using an antibody shown 
to inhibit monocyte-derived IL-l activity. In addition to con-
stitutive production, Langerhans cell production of ETAF/IL-
1 could be significantly augmented with either lipopolysaccha-
ride (20 J.Lg/ml) or with heat killed Staphylococcus albus (Fig 1), 
whi le keratinocytes did not significantly increase production 
with these stimulants. 
Physical Characteristics 
Both Langerhans cells and keratinocytes are thought to 
constitutive ly produce ETAF/IL-1. Although all methods of 
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FIG 1. Langer hans cell enriched, depleted, or unseparated epidermal 
cells (1 X 106 ) or monocytes (1 x 106), were cultured at 37•c for 72 h 
in RPM! 1640 with 10% heat inactivated human serum. Cells were 
stimulated with either 20 11g/ ml of lipopolysaccharide (LPS), or heat 
killed Staphylococc'us albus, or were unstimulated. Results are expressed 
in units/ml ETAF/IL-1 using the following formula: 
reciprocal titre of test sample 
at 30% maximal cpm of standard . . 
. 1 . 1. 3007 1. X 100 = umts/ml m sample rectproca tttre o · :~o o 
maximal cpm of standard 
The standard for this assay was derived from the skin squamous cell 
carcinoma cell line COL0-16. 
TABLE I. Effect of phenylglyoxal on ETAF activity 
Source of cytokine 
Monocytes 
Epidermal cells 
COL0-16 cells 
Residua l activity (% Control) 
13 mM PGO 65 mM PGO 
6 
27 
25 
N.D. 
5 
4 
Sephadex G-100 purified monocyte-derived IL-l or keratinocyte-
derived ETAF preparations were incubated with 13 mM or 65 mM 
phenylglyoxal (PGO) and after dialysis against phosphate buffered 
saline, residual activity in the thymocyte assay was determined. Activ-
ities in the control samples exposed to 20% ethanol were assigned 
100%. (N.D. = not done). 
obtaining Langerhans cell s and keratinocytes rely on enzyme 
treatment of skin , such treatment may in fact be a significant 
stimulus of ETAF production. Protein synthesis is required in 
order to recover biologic activity in cu lture supernatants. Treat-
ment of epidermal cells with cyclohexamide abrogates produc-
t ion ofETAF [3] . Biologic activity is generally detected within 
8 h of culture for both human and murine keratinocytes al-
t hough maximal levels are seen at 48- 72 h of cu lture. Then 
activity s lowly decreases [3]. ETAF, like IL-l is heat sensitive 
(inactivated by 80- 100·c for 10 min) and inactivated by ex-
t remes in pH (pH less than 3 or greater than 13) [3,4]. Phen-
ylglyoxal treatment inactivates ETAF, although in general, a 
higher concentration of phenylglyoxal is needed to inactivate 
ETAF than monocyte-derived IL-l (Table I- J Gauldie, A Koj, 
and DN Sauder, unpublished data). 
Gel filtration studies of both murine and human ETAF have 
demonstrated peak activ ity predominantly in the 15,000- 18,000 
M, range [3,4]. However, ETAF, like other hormone mediators , 
may be synthesized as a higher M , precursor. Activity is also 
seen at 35,000- 60,000 M, [6] . In addition, recent evidence 
suggests that lower M, species in the range of 4000 M, are a lso 
present (7]. Human ETAF, both normal epidermal cell-derived 
and keratinocyte cell line-derived, has three peaks by isoelectric 
focusing at approximately 6.8, 5.4, and 4.8 [8] . 
ETAF And Leukocytic Pyrogen 
Due to the simi larity (if not identity) of IL-l and leukocytic 
pyrogen (LP). studies were undertaken to determine whether 
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ETAF like IL-l could mediate fever. Using ETAF derived from 
normal human epidermal cell s as well as a human skin squa-
mous cell carcinoma cell line, we were able to induce a typical 
LP fever response [8] . Using Sephadex G-100 chromatography 
and tube gel isoelectric focusing, we were further able to show 
that peak fever activity corresponded to peak activity in t he 
thymocyte assay for ETAF/ IL-1. Furthermore, treatment of 
ETAF with an antibody against IL-1/ LP [8) caused inhibition 
of all activity in the thymocyte assay. Using the above antibody 
bound to Sepharose beads, we were able to inhibit fever activity 
and ETAF activity [8]. In addition, we were able to recover 
some, but not all of this activity from the antibody coated beads 
(Table II- DN Sauder and CA Dinarello, manuscript in prep-
aration). Using this antibody, we have also been able to im-
munoprecipitate ETAF (data not shown). 
EFFECT OF ETAF ON LEUKOCYTIC CHEMOTAXIS 
In vivo administration of ETAF was able to significantly 
increase the percent of peripheral blood neutrophils in rats (51 
± 7% compared to 10 ± 3% for control). In vitro partially 
purified ETAF was also shown to be a significant stimulus for 
neutrophil chemotaxis [8) . This represented true chemotaxis 
rather than chemokinesis [8]. In addition, this chemotactic 
activity corresponded to peak fever-inducing activity and max-
imum activity in the thymocyte assay. Using the aforemen-
t ioned ant ibody against IL-1/ LP, chemotactic activity was 
blocked, while chemotactic activity was unaffected by treat-
ment with anti-CS [8] . 
A variety of benign and neoplastic diseases affecting the skin 
are characterized histologically by T -cell infiltrates. Recent ly 
and perhaps of potential importance to such disorders, partic-
ularly cutaneous T -ce ll lymphomas is the observation that 
ETAF is a potent stimulus for T-cell chemotaxis. T cells 
purified by either rosetting and Ficoll hypaque centrifugation 
or by nylon wool fi ltration were labeled with [3H]uridine and 
then placed in a blind well modified Boyden chamber, using a 
double filter technique. The top filter was discarded and the 
bottom filter washed, then radioactivity was measured in a 
scintillation counter. Using this method, ETAF was found to 
be a potent, T-cell chemoattractant. This represented primarily 
true chemotaxis rather than chemokinesis. Fifty percent max-
imal activity (ED50) for chemotaxis was seen at a dilut ion of 
10-8 for column purified ETAF whereas EDso for the thymocyte 
assay was seen at 5 x 10-2 [9]. Thus, in addition to the potential 
pathophysiologic importance of the chemotactic property of 
ETAF, this T -cell chemotactic property may provide a sensitive 
assay for ET AF / IL-1. 
SYNTHESIS OF ACUTE-PHASE PROTEINS 
It has been shown that ETAF-containing preparat ions can 
induce the production of serum amyloid A in vivo. At all levels 
of purification, ETAF co-purified with serum amyloid A inducer 
[10]. Because of the complexities of in vivo systems, we chose 
to investigate whether ETAF could directly influence liver cell s 
to change the production of plasma proteins associated with 
TABLE II. Effect of anti-LP on fever-inducing activity of ETAF 
Activity of starting ma-
terial 
Activity of non bound 
material 
Activity of citric acid 
eluate 
ETAF/ IL-activity Fever 
cpm3 HTdR incorpo ration ~T ("C) 
5,442 ± 1,300 0.6 ± 0.08 
200 0 
2,463 ± 41 0.4 ± 0.04 
Crude ETAF was prepared from normal human epidermal cells. This 
material was then placed over a rabbit antihuman leukocytic pyrogen 
immuoabsorbent column. Bound material was eluted with citric ac id 
pH 3.2. ETAF/IL-1 activity was assayed in the standard thymocyte 
assay. Fever was assessed using the rabbit bioassay. 
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acute phase response. We studied in tissue culture the response 
patte rn of hepatic cells from 3 species using human hepatoma 
cells (HepG2 cells) and primary cultu res of rat and mouse 
hepatocytes. Each type of these liver cell s is characterized by a 
distinct set of acute phase plasma proteins. ET AF from the 
skin squamous ca rcinoma, COL0-16 cells, and from normal 
epidermal cell s were added to t he hepatic cells and 48 h later 
t he changes in t he synthesis and secretion of plasma proteins 
were determined by metabolic labeling. T hese ETAF-contain-
ing preparations were ab le to stimulate t he synt hesis of specific 
acute phase plasma proteins: a ,-antichymotrypsin in HepG2 
ce lls, a 1-ant ichymotrypsi n, a 1-acid glycoprotein and a2- macro-
globulin in rat hepatocytes, and a ,-acid glycoprotein , hapto-
globulin , and hemopexin in mouse hepatocytes [11] . The in -
creased production of plasma proteins could, at least in t he 
case of rat hepatocytes, be explained by an elevated level of 
functional mRNA [ll] . Comparing activit ies in the standard 
ETAF/IL-1 assay with the effects on plasma protein produc-
tion, we found some differences. Since no strict correlation was 
found between thymocyte- and hepatocyte-stimulating activ i-
t ies, t he presence of different sets of factors is assumed. 
Recently, we have developed a sensitive microassay for meas-
urement of hepatic synthesis of acute phase proteins, which 
allowed us to sc reen each column fract ion of monocyte or 
ep ide rmal derived cytokines. Using this microassay, we found 
that hepatocyte-stimulating activity was mainly in the M, range 
of 20,000- 30,000 compared to ETAF / IL- l (peak activity at 
15,000 M,) [12]. T his is consistent with the report of Ritchie 
and Fuller [13] who found t hat a human monocyte derived 
factor enhanced fibrinogen sec retion by rat hepatocytes eluted 
from a Sephadex G-75 column with a M, between 25,000-
30,000. In addition, we have recently examined high ly purified 
monocyte deri ved rat and rabbit IL-l which had high activity 
in the thymocyte co-stimulator assay. These highly purified 
preparations gave only minimal changes in hepatic synthesis 
of acute phase reactants (DN Sauder, R. Kampschmidt, and J 
Gau ldie, unpubli shed data). It is possible t hat ET AF / IL-l does 
not directly stimulate hepatocytes in vivo but rather may 
stimulate a second factor, a so-called hepatocyte-stimulating 
factor, which then leads to synthesis of acute phase proteins. 
T hus, epidermal cells (and monocytes) in addition to producing 
a facto r with ETAF/IL-1 activity a re a lso capable of producing 
a hepatocyte stimulating factor. 
ROLE OF ETAF IN T HE CATABOLIC PROCESS 
Accelerated proteolysis of muscle is a characteristic of 
t rauma, sepsis, and extensive thermal injury. LP / IL-l has been 
implicated in t he induction of such muscle protein degradation. 
Recent ly, we have shown t hat local t rauma in the form of 
thermal injury to murine skin can significant ly augment ETAF 
production. Using a cont rolled thermal injury in vivo to mice, 
we were able to increase ETAF activity from 75 units/ml in 
epidermal cell cul tu res derived from animals treated with 15-
min exposure at 37•c to 200 units/ml in epidermal cell cultures 
derived from an imals subjected to 55•c injury [7] . This led us 
TABLE Ill. In vit ro protein degradation (tyrosine release) induced in 
normal rat soleus muscle by incubation with ETAF 
SourceofETAF 
Normal epidermal cells (15,000 M, peak) 
COL0-16 (15,000 M, pea k) 
COL0-16 (4,000 M , peak) 
Bioactivity 
(% over control) 
55± 14 
37 ± 17 
47 ± 5 
ETAF prepared from either normal human epidermal cells or from 
the skin squamous cell carcinoma cell line COL0-16 was purified by 
Sephadex G-100 chromatography. Samples were then incubated with 
rat muscle for 2 h at 37"C. Net protein degradation was determined by 
measuring the rate of increase in tyrosine concentration in the incu-
bating medium at the beginning and end of the experiment. Control 
cultures had inactive ETAF added. 
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Frc 2. Effect of partially purified ETAF on fibroblast proliferation 
and collagen synthesis. 
to investigate whether ETAF -like LP / IL-l could induce muscle 
proteolysis. Two sources of cytokines were used; primary cul-
tures of normal human epidermal cells and t he skin squamous 
ce ll ca rcinoma cell line COL0-16. Muscle proteolysis was meas-
ured using the method of Clowes et al [14] . Sephadex G-100 
chromatography purified preparations (15,000 M, fraction) con-
taining high ETAF activity were used for this study. In addi-
tion, a 4000 M, fraction with high ETAF activity was a lso used. 
Results shown in Table Ill reveal significant muscle proteolysis 
induced by ETAF or a degradation product of ETAF [7] . 
EFFECT OF ETAF ON T CELLS 
While ETAF is a potent T-cell chemoattractant [9], it is not 
directly mitogenic for peripheral T cells or other lymphocytes. 
However, when varying dilutions of ETAF a re added to con-
canavalin A (Con A) stimulated murine spleen cells or Con A-
and phytohemagglutinin-treated human peripheral blood lym-
phocytes, significant increases in lnterleukin-2 (IL-2) activi ty 
was found in a dose-dependent manner [3]. Thus, ETAF c.an 
augment IL-2 production but has no IL-2 activity of its own. 
Epidermal cells or keratinocyte cell lines thus provide a con-
venient source of ETAF / IL-l that has no appreciable IL-2 
activity. 
AUTOCRINE EFFECTS OF ETAF 
To examine the possibility of autocrine growth stimulation 
by ETAF, exogenous ETAF was added to human kerati nocyte 
cell cultures. A previously described, serum-free hormone sup-
plemented keratinocyte culture system was used [15]. ETAF or 
heat inactivated ET AF was added to the keratinocyte cultures 
at each feeding. After 7 days there was a linear dose response 
to ETAF with an increase in cells from 1.9 X 106 (control) to 
2. 7 x 106 cells/dish at 100 units/ml with a parallel increase in 
both total protein content (170 mg/dish-300 mg/dish) and 
colony size. Cultures treated with heat inactivated ETAF were 
ident ical to control cultures [16], suggesting that ETAF pro-
duction may contribute to autocrine growth stimulation of 
kerat inocytes. ET AF is also mitogenic for fibroblast and is 
capable of increasing fibroblast proliferation (Fig 2), (DN Sau-
der and M Cathcart, unpublished data, and [17]) . Thus, ET AF 
through its effect on fibroblast and keratinocyte proliferation, 
may play a significant role in wound healing and perhaps 
normal cutaneous homeostasis. 
Thus, ETAF appears to have a mult iplicity of divergent 
biological effects: enhancement of thymocyte proliferation, 
stimulation of cells in t he hypotha lamus to mediate fever, 
stimulation of leukocyte chemotaxis, stimulation of hepatic 
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synthesis of acute phase proteins, induction of muscle proteo-
lysis, augmentation of IL-2 production, fibroblast and keratin -
ocyte growth stimulatio n. However, it is unclea r whether these 
divergent activi t ies are mediated by one single cytok ine as is 
true for other hormones or whether these divergent activities 
are mediated by severa l different but closely related cytokines 
as is the case with interferons. In either case, ETAF- like IL-l 
may play an important role in both local cutaneous and sys-
temic inflammatory and immunologic events. 
REFERENCES 
1. Silberberg 1: Ultrastructura l studies of Langerhans cells in contact 
sensitive and primary irritant reactions to mercuric chloride. 
Cli n Res 19:715A, 1971 
2. Sting! G, Katz SI, Clement L, Green I, Shevach EM: Detection of 
Ia antigens on Langerhans cells in guinea pig ski n. J Immunol 
121:2005-2013, 1978 
3. Saunder DN, Carter C, Katz Sl, Oppenheim JJ : Epidermal cell 
production of t hymocyte activation factor (ETAF) . J Invest 
Dermatol 79:34- 39, 1982 
4. Luger TA, Stadler BM, Katz Sl, Oppenheim JJ : Epidermal ce ll 
(keratinocyte) derived t hymocyte activating facto r. J lmmunol 
127:1493- 1498, 1981 
5. Wysocki LJ, Sato YL: "Panning" for lymp hocytes: a method for 
cell selection. Proc Natl Acad Sci USA 75:2844- 2850, 1978 
6. Sauder DN, Dinarello CA, Morhenn VB: Langerhans cell produc-
tion of in terleukin -1. J Invest Dermatol 82:605-607, 1984 
7. Sauder ON, George BC, Clowes GHA: Human epidermal cell 
derived cytokine stimulation of muscle proteolysis. Clin Res 32: 
613A, 1984 
8. Sauder DN, Mounessa NL, Katz S l, Dinarello CA, Gallin Jl: 
Chemotactic cytokines: the role of leukocytic pyrogen and epi-
PROPERTIES OF ETAF 179s 
dermal cell derived thymocyte activating factor in neutrophil 
chemotaxis. J lmmunol 132:828-832, 1984 
9. Sauder DN, Monick M, Hunninghake G: Human epidermal cell 
derived thymocyte activating factor is a potent T -cell chemoat-
tractant. Clin Res 32:613, 1984 
10. Sztein MB, Luger TA, Oppenheim JJ: An epidermal cell derived 
cytokine triggers in vivo synthesis of serum amyloid A by hepa-
tocytes. J Immunol 129:87-90, 1982 
11. Baumann H , Jahreis GP, Sauder DN, Koj A: Human keratinocytes 
and monocytes release factors which regulate the synthesis of 
major acute phase plasma proteins in hepatic cells from ma n 
rat and mouse. J Bioi Chern 259:7331-7342, 1984 ' 
12. Koj A, Gauldie J , Sweeney GD, Regoeczi E, Sauder DN: A single 
bioassay for monocyte derived hepatocyte stimulating factor: 
increased synthesis of a lpha 2 macroglobulin a nd reduced syn-
thesis of albumin by cultured rat hepatocytes. J lmmunol Met h-
ods 76:317- 327, 1985 
13. Ritchie DG, Fuller GM: Hepatocyte stimulating factor: a monocyte-
derived acute-phase regulatory protein. Ann NY Acad Sci 
408:490-500, 1983 
14. Clowes GHA, George BC, Villee CA, Sarvais CA: Muscle proteo-
lysis induced by circulating peptide in patients with sepsis or 
trauma. N Eng! J Med 308:545-552, 1983 
15. Gi lchrest BA, Calhoun JK, Maciag T: Attachment and growth of 
human keratinocytes in a serum-free environment. J Cell Physiol 
112:197-206, 1982 
16. Gilchrest BA, Sauder DN: Autocrine growth stimulation of human 
keratinocytes by epidermal cell -derived thymocyte activating 
factor (ETAF), implications for cellular aging. Clin Res 32:585A, 
1984 
17. Luger TA, Stadler BM, Luger BM, Sztein MB, Schmidt JA, Haw-
ley-Nelson P, Grabner G, Oppenheim JJ: Characteristics of a n 
epidermal cell thymocyte activating factor (ET AF) produced by 
human epidermal cells and a human squamous cell carcinoma 
cell line. J Invest Dermatol 81:187-193, 1983 
